Trastuzumab Deruxtecan [Enhertu] 

The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating patients with human epidermal growth factor receptor 2 (HER2)-low unresectable and/or metastatic breast cancer who have received at least one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. The decision was based on the unfavourable cost-effectiveness of T-DXd compared with chemotherapy, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.

The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have received two or more prior therapies. The decision was based on the unfavourable cost-effectiveness of T-DXd at the price proposed by the company compared with chemotherapy.

Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.

The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic breast cancer after a prior anti-HER2-based regimen. The decision was based on the uncertain extent of clinical benefit and unfavourable cost-effectiveness of T-DXd at the price proposed by the company compared with alternative treatments.

Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.